Skip to Main Content

WASHINGTON — Lawmakers will wade through more than 100 potential amendments when the Senate Finance Committee takes up its sweeping new drug pricing package on Thursday.

Some of the amendments could significantly rework the package, like an amendment from Sens. Pat Toomey (R-Pa.) and Pat Roberts (R-Kan.) that would eliminate the controversial provisions in the bill that would restrict drug makers from raising prices beyond the rate of inflation. A separate amendment from Sen. John Cornyn (R-Texas) would only allow that provision to go into effect if HHS certifies it won’t lead to higher launch prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!